Loss of MLH1 confers resistance to PI3Kβ inhibitors in renal clear cell carcinoma with SETD2 mutation

Tumor Biology

Volumn 36, Issue 5, 2015, Pages 3457-3464

  Feng, Chenchen ^a   Ding, Guanxiong ^a   Jiang, Haowen ^a   Ding, Qiang ^a   Wen, Hui ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Clear cell renal cell carcinoma; MLH1; MMR; SETD2

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE BETA; PHOSPHATIDYLINOSITOL 3 KINASE BETA INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PROTEIN MLH1; UNCLASSIFIED DRUG; HISTONE LYSINE METHYLTRANSFERASE; MLH1 PROTEIN, HUMAN; NUCLEAR PROTEIN; SET2 PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ARTICLE; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COMPUTER MODEL; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME PHOSPHORYLATION; GENE DELETION; GENE MUTATION; GENE SILENCING; GENETIC ASSOCIATION; GENOME; GENOMICS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MISMATCH REPAIR; MUTANT; PRIORITY JOURNAL; PROTEIN DEPLETION; SETD2 GENE; TUMOR GENE; WILD TYPE; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; DRUG RESISTANCE; GENETICS; KIDNEY NEOPLASMS; MUTATION; PHYSIOLOGY; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; DNA MISMATCH REPAIR; DRUG RESISTANCE, NEOPLASM; GENE DELETION; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; KIDNEY NEOPLASMS; MUTATION; NUCLEAR PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84929956729     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2981-y     Document Type: Article

References (23)

1. Linehan WM. Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics. Genome Res. 2012;22:2089–100.
2. Guo G et al. Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genet. 2012;44:17–9.
3. Dalgliesh GL et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature. 2010;463:360–3.
4. Varela I et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature. 2011;469:539–42.
5. Garnett MJ et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012;483:570–5.
6. Li F et al. The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSalpha. Cell. 2013;153:590–600.
7. Zhu X et al. Identification of functional cooperative mutations of SETD2 in human acute leukemia. Nat Genet. 2014;46:287–93.
8. Cancer Genome Atlas Research. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499:43–9.
9. Gao J et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:l1.
10. Cerami E et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–4.
11. Ding G et al. Combination of rapamycin, CI-1040, and 17-AAG inhibits metastatic capacity of prostate cancer via slug inhibition. PLoS ONE. 2013;8:e77400.
12. Wen H et al. Med19 promotes bone metastasis and invasiveness of bladder urothelial carcinoma via bone morphogenetic protein 2. Ann Diagn Pathol. 2013;17:259–64.
13. Feng C-C et al. Expression of pigment epithelium-derived factor and tumor necrosis factor-α is correlated in bladder tumor and is related to tumor angiogenesis. Urol Oncol Semin Original Investig. 2013;31:241–6.
14. Rubio-Del-Campo A et al. Implications of mismatch repair genes hMLH1 and hMSH2 in patients with sporadic renal cell carcinoma. BJU Int. 2008;102:504–9.
15. Dail, M. et al. Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia. Nature (2014).
16. Choi YJ et al. Frameshift mutation of a histone methylation-related gene SETD1B and its regional heterogeneity in gastric and colorectal cancers with high microsatellite instability. Hum Pathol. 2014;45:1674–81.
17. Hakimi AA et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res. 2013;19:3259–67.
18. Schmidt CK, Jackson SP. On your mark, get SET(D2), go! H3K36me3 primes DNA mismatch repair. Cell. 2013;153:513–5.
19. Pfister SX et al. SETD2-dependent histone H3K36 trimethylation is required for homologous recombination repair and genome stability. Cell Rep. 2014;7:2006–18.
20. Jia J et al. A novel function of protein kinase B as an inducer of the mismatch repair gene hPMS2 degradation. Cell Signal. 2013;25:1498–504.
21. Stoehr C et al. Mismatch repair proteins hMLH1 and hMSH2 are differently expressed in the three main subtypes of sporadic renal cell carcinoma. Pathobiology. 2012;79:162–8.
22. Singh RB, Amare Kadam PS. Investigation of tumor suppressor genes apart from VHL on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC). Urol Oncol. 2013;31:1333–42.
23. Wang SS et al. Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis. Proc Natl Acad Sci U S A. 2014;111:16538–43.